A three-year collaboration between Ablynx NV and Merck & Co. Inc in immuno-oncology has been extended by one year in order to enable the parties to investigate up to 12 new molecules targeting individual protein targets and combinations of targets that could potentially treat cancer, Ablynx announced the new agreement on 22 July.
